Investor's Business Daily
2 Top Biotechs Presenting Data At Hematology Event
From Saturday through Tuesday, reps from drugmakers around the world will be gathering in New Orleans to present data on their blood-disease drugs at the American Society of Hematology conference.
RDInvesting Provides Investors with Free In-Depth Equity Reports on...
Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events.
Celgene Rises As UBS Upgrades Shares to 'Buy'
THE SPARK: Analyst Matthew Roden raised his rating to "Buy" from "Neutral" and increased his price target to $200 per share from $163.
Thu Dec 05, 2013
Facebook, Celgene And Blackrock: Bagging Strong Stocks At Good Prices
In today's choppy market, it pays not to chase stocks, but instead to let stocks come to you via orderly and constructive pullbacks and buy them as they emerge from low risk buy points.
On The Fly: Analyst Initiation Summary
Check below for free stories on ARRS;CVLT;BSX;COV;LMOS;RDN;ACMP;SPR;SRC;PSEC;NCFT;TWO;ATTU;TNGO;AGNC;FAF;ESNT;FNF;PAYX;SLG;ENTG;CCMP;MEIP;PVA;BCRH the last two weeks.
The Zacks Analyst Blog Highlights: Celgene, Biogen, Gilead, Orexigen and Cubist
Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.
Wed Dec 04, 2013
Shares of OncoMed Double on Celgene Pact and New Pancreatic Cancer Drug Trial
On Tuesday, shares OncoMed Pharmaceuticals, Inc. catapulted nearly 100 percent to surpass the closing price from their IPO day back in July on news that the Redwood City, California -based drug maker had agreed with Celgene Corp. to jointly develop and commercialize up to six anti-cancer stem cell product candidates in the OncoMed pipeline.
ALLIQUA, INC. FILES (8-K) Disclosing Change in Directors or Principal ...
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Tue Dec 03, 2013
Investor's Business Daily
Stock Market Today: Celgene, Biotechs Lead Selloff
Stocks sold off in higher volume Tuesday on renewed concerns that the Federal Reserve will start to scale back its stimulus program.
Mid-Afternoon Market Update: Strong U.S. Auto Sales Numbers Unable to Buoy Market as Indexes Go Red
Toward the end of trading Tuesday, the Dow traded down 0.81 percent to 15,879.09 while the NASDAQ tumbled 0.46 percent to 4,026.29.
Opportunities For Sorrento After Acquisition Of ADC Tech
After some new and aggressive developments, we are once again taking a look at Sorrento Therapeutics .
's Top #PreMarket Gainers
OncoMed Pharmaceuticals surged 80.40% to $25.40 in the pre-market session on deal to sell 1.47 million shares to Celgene at $15.13 per share.
OncoMed and Celgene Announce Strategic Collaboration Advancing...
Celgene Invests in OncoMed's Demcizumab and up to Five Additional Preclinical Biologics Programs; OncoMed Leads Early Clinical Trials and Retains Co-Development, Co-Commercialization and Profit-Sharing Rights REDWOOD CITY, Calif., Dec. 3, 2013 -- OncoMed Pharmaceuticals, Inc. and Celgene Corporation today announced an agreement to jointly develop ... (more)
Mon Dec 02, 2013
Acceleron Announces New Interim Phase 2 Sotatercept Clinical Data in...
Acceleron Pharma Inc. , a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that data in five abstracts for sotatercept and ACE-536, Acceleron's programs to treat red blood cell disorders, will be presented at the 55th ... (more)
Mon Nov 25, 2013
NASDAQ Gainers Watch List: Celgene Corporation (NASDAQ:CELG) and...
Equity Profile Report expands its NASDAQ Gainers Weekly Watch List adding Celgene Corporation and Marvell Technology Group Ltd. .
Five Star Equities Issues New Research Reports on BIIB, CELG, DVA and ...
Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns.
Fri Nov 22, 2013
Investor's Business Daily
Inside IBD 50: Biogen, Celgene Muscle Higher
Amid a generally tame week for the major indexes and just three trading days ahead of the Thanksgiving holiday, the IBD 50 continued to showcase some big movers, both on the upside and downside.
Wall Street Journal
Celgene's Cancer Drug Gets Support
Celgene Corp. received a positive opinion for its pancreatic-cancer treatment Abraxane from the European Medicines Agency's Committee for Medicinal Products for Human Use, paving the way for potential approval of the treatment.
Celgene International S??rl Receives Positive Opinion For ABRAXANE??...
Celgene International SA rl Receives Positive CHMP Opinion For ABRAXANEA In Combination With Gemcitabine As Treatment For Patients With Metastatic Pancreatic Cancer Celgene Receives Positive CHMP Opinion for ABRAXANEA in Combination with Gemcitabine as Treatment for Patients with Metastatic Pancreatic Cancer BOUDRY, Switzerland-- -- Celgene ... (more)
Celgene Receives Positive CHMP Opinion For ABRAXANE® in...
Celgene International Sarl, a wholly-owned subsidiary of Celgene Corporation , today announced that the European Medicines Agency's : Committee for Medicinal Products for Human Use has adopted a positive opinion for ABRAXANE in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.